Absci (ABSI) vs Charles River Laboratories International (CRL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Absci (ABSI) has outperformed Charles River Laboratories International (CRL) over the past year, gaining 146.5% versus a gain of 76.5%. Over five years, ABSI leads with a -13.3% price change compared with -25.6% for CRL. Charles River Laboratories International is the larger company by market cap ($14.35 billion vs $1.53 billion), about 9.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | CRL |
|---|---|---|
| Share price | $8.94 | $298.00 |
| Market cap | $1.53B | $14.35B |
| 1-day change | -3.04% | -0.77% |
| YTD return | +164.18% | +50.54% |
| 1-year return | +146.52% | +76.54% |
| 5-year return | -13.26% | -25.58% |
| Forward P/E | — | 23.33 |
| EPS (TTM) | $-0.79 | $-4.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.02B |
| Revenue growth (YoY) | — | -0.85% |
| Net income (latest FY) | — | $-144.34M |
| Operating margin | — | 0.63% |
| Net margin | — | -3.59% |
| 52-week high | $12.06 | $333.30 |
| 52-week low | $2.24 | $146.20 |
| Distance from 52-week high | -25.84% | -10.59% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +61.07% | +2.35% |
| Average volume | 3.45M | 947.94K |
| Shares outstanding | 171.61M | 48.17M |
| Employees | 140 | 18,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Charles River Laboratories International is about 9.4 times larger than Absci by market value ($14.35B vs $1.53B).
- ABSI has outperformed CRL by 70.0 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Charles River Laboratories International
CRL stock →Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 18,300 employees
ABSI vs CRL FAQ
Which is bigger, Absci or Charles River Laboratories International?
Charles River Laboratories International (CRL) is larger, with a market capitalization of $14.35B compared with $1.53B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or CRL?
ABSI returned +146.52% over the past 12 months, compared with +76.54% for CRL (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Charles River Laboratories International in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.